Understanding and overcoming resistance to immunotherapy in genitourinary cancers

Understanding and overcoming resistance to immunotherapy in genitourinary cancers

ABSTRACTThe introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (ICIs) like nivolumab, ipilimumab, pembrolizumab, a...

Full description

Bibliographic Details
Main Authors:	Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu, Mehmet Asim Bilen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Cancer Biology & Therapy
Subjects:	Nivolumab ipilimumab programmed cell death protein-1 (PD-1) programmed death ligand-1 (PD-L1) immune checkpoint inhibitors immunotherapy resistance
Online Access:	https://www.tandfonline.com/doi/10.1080/15384047.2024.2342599

Similar Items

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
by: Lucas V. dos Santos, et al.
Published: (2021-03-01)

Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives
by: Gerardo Cazzato, et al.
Published: (2023-06-01)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
by: Ismael Rodriguez, et al.
Published: (2023-09-01)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
by: Niki Karachaliou, et al.
Published: (2015-06-01)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2021-07-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)

Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01)

Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy
by: Tiziana Vavalà
Published: (2018-06-01)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
by: Koichi Furukawa, et al.
Published: (2020-08-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
by: Margarita Udall, et al.
Published: (2018-02-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases
by: Dominika Katarzyna Madras, et al.
Published: (2020-04-01)

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner
by: Christodoulos Filippis, et al.
Published: (2017-12-01)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
by: Ze Xiang, et al.
Published: (2022-05-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01)

Gut microbiome for predicting immune checkpoint blockade-associated adverse events
by: Muni Hu, et al.
Published: (2024-01-01)

PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy
by: Li Chen, et al.
Published: (2022-05-01)

Breast Cancer Immunotherapy: From Biology to Current Clinical Applications
by: Jorge Henrique Santos Leal, et al.
Published: (2020-06-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
by: Yuedi Zhang, et al.
Published: (2022-06-01)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
by: Fengze Sun, et al.
Published: (2022-03-01)

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
by: Keywan Mortaezaee, et al.
Published: (2023-07-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
by: Fabio Scirocchi, et al.
Published: (2022-11-01)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
by: Ernesto Rossi, et al.
Published: (2019-07-01)

The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
by: Keywan Mortezaee, et al.
Published: (2023-06-01)

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)

Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
by: Selina K. Wong, et al.
Published: (2021-11-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
by: Hidehito Horinouchi, et al.
Published: (2019-09-01)

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer
by: Kishan R. Bharadwa, et al.
Published: (2022-01-01)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
by: Mohammadsaleh Jahangir, et al.
Published: (2022-12-01)

Advances in immunotherapy for treatment of lung cancer
by: Jean G. Bustamante Alvarez, et al.
Published: (2015-09-01)

Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
by: Ahmad Monabati, et al.
Published: (2020-07-01)

Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
by: Shinada K, et al.
Published: (2023-02-01)